Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

Another good day

Plethora Solutions (LON:PLE) is still very much in the sights of small cap investors. Today, punters were speculating about a possible takeover from drug giant Pfizer following Friday’s news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given its treatment for premature ejaculation their seal of approval.

The AIM-listed company received a “positive opinion” from the committee for PSD502 in one of the last few steps before marketing authorisation is granted by the European Commission (EC).

The decision will be reviewed by the EC, which has the power to give medicines the green light in Europe. It thinks a final decision will arrive shortly from the EC – typically around 60 days after a CHMP recommendation.

Before todays rise -


Plethora Solutions Plc (PLE): Target Towards 12p

http://www.directorstalk.com/plethora-solutions-plc-ple-target-towards-12p-despite-recent-gains-chart-and-commentary/

In shares today - watch the cash position as they are burning it.

INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2013

RNS


RNS Number : 1858P

Plethora Solutions Holdings PLC

30 September 2013












PLETHORA SOLUTIONS HOLDINGS PLC

("Plethora" or the "Company")

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2013



Plethora is pleased to announce its interim results for the six months ended 30 June 2013.



Highlights



· Refocusing of business solely on PSD502



· Successful placing raising £2.1 million together with debt restructuring



· Now responsible for regulatory and commercial development of PSD502 globally



· Strengthening of Plethora board



· A CHMP positive opinion in relation to PSD502 approval for European Union in September 2013



Ronald Openshaw, CEO of Plethora said:



"2013 has so far been an exceptional year for Plethora, We have focussed the Group's full effort on PSD502; expanded our geographic interest in the product; commenced work on the filing with the FDA in the United States and achieved a milestone in the European regulatory process. Our efforts are to ensure that PSD502 is brought to market to ease the distress of so many couples".





- Ends -

Moving up nice, on a poor markets day.

probably reverse a bit more as from 20th September it is approximately 60 days after a CHMP recommendation to final decision - then imo watch it really fly on receipt of that

Up 11%

UPDATE - Plethora Solutions' cash call supported by institutions
By Giles Gwinnett October 15 2013, 4:51pm It will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it saidIt will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it said

Plethora Solutions (LON:PLE) is to raise £4.4mln to advance its treatment for premature ejaculation.



The company is issuing 49mln shares that will be purchased at 49p a pop, primarily by institutional investors, including funds associated with Jim Mellon, Plethora’s non-executive chairman.

Shares in Plethora closed at 11.13p the day before the share issue was announced.

"The proceeds of this financing will be used to complete the last steps of regulatory approval in the Europe, but importantly will fund the filing and prosecution of a New Drug Application (NDA) with the US Food and Drug Administration (FDA),” the company said in a statement.

It will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it said.

The company disclosed that 22.33mln shares will be available through subscription, raising £2.0mln; of this, £1.8mln will come from entities associated with Jim Mellon. A further £100,000 will be subscribed to by other directors, including chief executive Ronald Openshaw, chief scientific officer Professor Michael Wyllie and non-executive director Dr Greg Bailey.

Institutional investors will sign up for 26.7mln shares to raise £2.4mln.

"Over the last few months Plethora has delivered the agreement to control global development and commercialisation of PSD502 and the positive opinion from the CHMP. Based on the positive effect on the company's valuation we have secured the resources to execute our near term strategy of seeing approval of PSD502 and generating a financial return to shareholders," Openshaw said.

This is looking good for the next fw months..potential for the share of 2014! (imho, dyor!)

another very good day - likely to end the week circa 20p
gl

onwards & upwards :-0

Hopefully see this pick up again from November onwards. Could be truly amazing.

Up 13.5%

Up 22%

Closed up just under 26%

hope you are in dc - another fantastic day
atb

:-))

looking strong before eu approval rubber stamping rns now the merlin overhang cleared